MX2018013324A - Métodos y composiciones para el tratamiento del síndrome de rett. - Google Patents

Métodos y composiciones para el tratamiento del síndrome de rett.

Info

Publication number
MX2018013324A
MX2018013324A MX2018013324A MX2018013324A MX2018013324A MX 2018013324 A MX2018013324 A MX 2018013324A MX 2018013324 A MX2018013324 A MX 2018013324A MX 2018013324 A MX2018013324 A MX 2018013324A MX 2018013324 A MX2018013324 A MX 2018013324A
Authority
MX
Mexico
Prior art keywords
methods
rett syndrome
compositions
treatment
bryostatin
Prior art date
Application number
MX2018013324A
Other languages
English (en)
Inventor
Benison Jeffrey
L Alkon Daniel
Original Assignee
Neurotrope Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotrope Bioscience Inc filed Critical Neurotrope Bioscience Inc
Publication of MX2018013324A publication Critical patent/MX2018013324A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud proporciona métodos para tratar sujetos humanos que sufren del Síndrome de Rett administrando activadores de PKC, por ejemplo, briostatina 1, otras briostatinas y briólogos; la presente divulgación proporciona, de conformidad con ciertas modalidades, métodos que comprenden administrar a un sujeto con síndrome de Rett una cantidad farmacéuticamente efectiva de briostatina 1.
MX2018013324A 2016-05-04 2017-05-04 Métodos y composiciones para el tratamiento del síndrome de rett. MX2018013324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662331913P 2016-05-04 2016-05-04
PCT/US2017/031144 WO2017192906A1 (en) 2016-05-04 2017-05-04 Methods and compositions for treatment of rett syndrome

Publications (1)

Publication Number Publication Date
MX2018013324A true MX2018013324A (es) 2019-08-01

Family

ID=60203633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013324A MX2018013324A (es) 2016-05-04 2017-05-04 Métodos y composiciones para el tratamiento del síndrome de rett.

Country Status (10)

Country Link
US (1) US20190125721A1 (es)
EP (1) EP3452482A4 (es)
JP (1) JP2019514961A (es)
KR (1) KR20190005158A (es)
CN (1) CN109071559A (es)
AU (1) AU2017261287A1 (es)
CA (1) CA3020226A1 (es)
IL (1) IL262547A (es)
MX (1) MX2018013324A (es)
WO (1) WO2017192906A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110960599B (zh) * 2019-12-31 2023-11-07 西安交通大学医学院第二附属医院 瑞香狼毒总生物碱的提取方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825229B2 (en) * 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20040167217A1 (en) * 2003-02-26 2004-08-26 Giovanni Scapagnini Neuroprotective effects of polyphenolic compounds
CN101506218A (zh) * 2005-05-23 2009-08-12 麻省理工学院 含有多不饱和脂肪酸的组合物及其使用方法
US20090029873A1 (en) * 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
CN101011355B (zh) * 2006-02-01 2013-01-02 陈献 经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
AU2007238608A1 (en) * 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
CA2659242C (en) * 2006-07-28 2015-08-11 Blanchette Rockefeller Neurosciences Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
US20090016975A1 (en) * 2007-07-12 2009-01-15 Robert Bianchini Fade-resistant coloring composition containing an acid dye and a cationic conditioning agent for a keratin-containing substrate
WO2009099563A2 (en) * 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
JP6062362B2 (ja) * 2010-08-19 2017-01-18 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｐｋｃ活性化剤を使用した、異常な樹状突起棘に関連した認知障害の治療
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
CN105456298A (zh) * 2015-12-01 2016-04-06 中国人民解放军第二军医大学 草苔虫总内酯抗老年痴呆活性及其应用

Also Published As

Publication number Publication date
KR20190005158A (ko) 2019-01-15
CA3020226A1 (en) 2017-11-09
US20190125721A1 (en) 2019-05-02
CN109071559A (zh) 2018-12-21
AU2017261287A1 (en) 2018-10-25
EP3452482A4 (en) 2020-01-01
JP2019514961A (ja) 2019-06-06
IL262547A (en) 2018-12-31
EP3452482A1 (en) 2019-03-13
WO2017192906A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
PH12021550872A1 (en) Therapeutic compounds
MX2022003037A (es) Compuestos antibacterianos.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
GEP20247585B (en) Furoindazole derivatives
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2021014987A (es) Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.
MX2018013324A (es) Métodos y composiciones para el tratamiento del síndrome de rett.
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.